MediQuest Therapeutics said Friday that the U.S. Food and Drug Administration turned down its application to launch a treatment to treat Raynaud's Disease.

Share story

MediQuest Therapeutics said Friday that the U.S. Food and Drug Administration turned down its application to launch a treatment to treat Raynaud’s Disease.

The Bothell-based company said it received an FDA letter saying that the treatment “could not be approved in its present form.” The agency identified issues that need to be addressed by the company, but such issues were not disclosed. The company said it will provide an update “when appropriate.” The news was first reported by the website Xconomy.

MediQuest had requested expedited approval for what would have been the first product marketed for Raynaud’s disease, an ailment that constricts blood flow to the extremities.

Mediquest has 25 employees and has raised some $33 million from investors since 2006.

Ángel González: 206-515-5644 or agonzalez@seattletimes.com